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PlateletsClopidogrel is an oral antiplatelet pro-drug prescribed to 40 million patients worldwide who are at risk for
thrombotic events or receiving percutaneous coronary intervention (PCI). However about a ﬁfth of patients
treated with clopidogrel do not respond adequately to the drug. From a cohort of 105 patients on whom we
had functional data on clopidogrel response, we used ultra-high throughput sequencing to assay mutations in
CYP2C19 and ABCB1, the two genes genetically linked to respond. Testing for mutations in CYP2C19, as
recommended by the FDA, only correctly predicted if a patient would respond to clopidogrel 52.4% of the
time. Similarly, testing of the ABCB1 gene only correctly foretold response in 51 (48.6%) patients. These results
are clinically relevant and suggest that until additional genetic factors are discovered that predict response
more completely, functional assays are more appropriate for clinical use.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Clopidogrel is an oral antiplatelet pro-drug prescribed to 40 mil-
lion patients worldwide who are at risk for thrombotic events or re-
ceiving percutaneous coronary intervention (PCI) [1]. Many studies
have demonstrated the efﬁcacy of its use in addition to aspirin to pre-
vent death, myocardial infarction, and stroke in patients with coro-
nary syndromes. The FDA currently recommends clopidogrel as a
therapy administered once daily for 365 days for patients undergoing
PCI [1,2]. Clopidogrel has an irreversible antagonistic effect on the
adenosine diphosphate (ADP) P2Y12 receptor and has been shown
to signiﬁcantly improve clinical outcomes in patients who respond
to the medication [2–5]. However, the response to clopidogrel varies.
About a ﬁfth of patients treated with clopidogrel do not respond ade-
quately due to decreased absorption, inadequate conversion to its ac-
tive metabolite, or other reasons such as increased body mass index,
diabetes mellitus, and acute coronary syndrome [6,7]. Interactions
with other medications, such as the proton pump inhibitor omepra-
zole, have been also identiﬁed as responsible for the lack of effective-
ness of clopidogrel [1].
Clopidogrel is administered orally, absorbed through the intestine,
and then metabolized to its active form in the liver by cytochrome P450ter, 223NorthVanDienAvenue,
.
rights reserved.enzymes in a two-step process [6,7]. Two genes, ABCB1 and CYP2C19,
have been identiﬁed as important players in this process. ABCB1 encodes
the P-glycoprotein efﬂux transporter, which is responsible for absorbing
clopidogrel from the intestine [6–8]. CYP2C19 (Cytochrome P450 2C19)
encodes a member of the cytochrome P450 superfamily of enzymes
which catalyze many reactions involved in drugmetabolism and synthe-
sis of cholesterol, steroids and other lipids.
The CYP2C19*2 (G681A) and ABCB1 (C3435T) variants are the most
common loss-of-functionmutations described in the literature [1,9,10].
Patients with these variants are classiﬁed as low- or non-responders to
clopidogrel and tend to have higher platelet reactivity, which places
them at risk for adverse cardiovascular events [6,8,10–12]. However,
the Genotype Information and Functional Testing (GIFT) study has
cited CYP2C19*2, not ABCB1 or other variants, as the crucial gene variant
that signiﬁcantly inﬂuences the reactivity and pharmacodynamics of
clopidogrel in patients who have undergone PCI [10]. Nevertheless,
Price and colleague note that this piece of genetic data provides only
limited utility in patients who exhibit the potential for high adverse re-
activity to clopidogrel [10].
A patient's likely functional response to clopidogrel can be assessed
by pre-administration genetic testing. There are two bedside genetic
tests currently used, but they require long wait times and are tested
only for speciﬁc allele variations; the CYP2C19 genotype has been
shown to account for just 12% of the variation of clopidogrel response
[9]. For these reasons, a functional platelet inhibition test (PIT) has
become a more practical choice in clinical practice. The VerifyNow
P2Y12 assay (Accumetrics, San Diego, CA) uses whole blood tomeasure
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sure to prostaglandin E1 and ADP [7,10,13]. Patients with VerifyNow
scores >240 P2Y12 reaction units (PRU) have a higher risk for
cardiovascular-related death, stent thrombosis, and non-fatal myocar-
dial infarction [3–5,14]. This >240 PRU cut-off is comparable to the
established thresholds for other PITs such as light transmittance
aggregometry, Plateletworks, and Innovance PFA P2Y assays (Breet,
van Werkum et al., 2010). However, there is only a modest correlation
between these tests and cardiovascular (CV)-related death, stent
thrombosis, or non-fatal MI [3,5].
In a previous study, we demonstrated the beneﬁt of using a PIT
(without genetic testing) to guide the timing of coronary surgery
for patients receiving clopidogrel [15]. Since then, genetic testing
has become widely available and endorsed by the FDA [16]. With
this current study, our goal was to validate in our surgical series of pa-
tients a genetic screen with a functional PIT (VerifyNow) to ascertain
the true yield of these new assays against a functional test.
2. Results
Of the 105 patients analyzed, 71 (67.62%) were deemed non-
responders by the VerifyNow Assay. Non-responders were more like-
ly to female, older, not current smokers, diabetics, with a history of
renal failure and taking beta blockers and ADP inhibitors (Table 1).Table 1
Patient demographics.




Weight (kg) 85.2 17.3
Height (cm) 172.4 9.9 1
Body surface area 2.01 0.24
Body mass index 28.62 4.95
History of Smoking 59 56.2%









Chronic lung disease 9.5%
Immuno-suppressed 2 1.9%
Peripheral vascular disease 11 10.5%
Pacemaker 2 1.9%
Cardiac History
Myocardial infarction 55 52.4%
Cerebrovascular accident 3 2.9%
Cardiovascular disease 11 10.5%
Percutaneous coronary intervention 35 33.3%




Beta blockers 98 93.3%






ADP inhibitors 21 20.0%
Glycoprotein IIbIIIa inhibitor 2 1.9%
# of diseased vessels 2.9 0.4
Left main disease 56 53.3%
Ejection fraction 52.7 11.4
30-day mortality 1 0.95%
Late mortality 8 8.6%
Total mortality 9 9.5%The genome sequencing mutation detection results are presented
in Table 2. Overall, 17 patients (16.2%) had no mutations in either
ABCB1 or CYP2C19. Of these, 7 responded to the drug and 10 were
non-responders. Mutations were common in the ABCB1 gene, with
76.2% of patients having the C3435T variation. About a third of pa-
tients (32.4%) had a loss-of-function mutation in CYP2C19, with a ma-
jority of these showing the*2 variant (G636A) (29.5%) compared to
the 1.9% and 1.0% of *4 (C1297T) and *8 (T358C) variants, respective-
ly. 23 patients had mutations in both genes. We were unable to deter-
mine frequency of *17 variants (T-808C) as the mutation occurs in an
intron and our experimental design assayed only the exons.
Twenty-four of the 34 patients with a CYP2C19 loss-of-function mu-
tation were non-responders (p = 0.414). Similarly, of the 80 patients
with a loss-of-function mutation in ABCB1, 55 were non-responders
(p = 0.483). CYP2C19 mutations were found in 10 (29.41%) of re-
sponders and in 24 (33.80%) of non-responders. The C3435T ABCB1 var-
iant was found in 25 (73.53%) responders and in 55 (77.46%) non-
responders. A chi-square analysis showed non-signiﬁcance (p = 0.781).
3. Discussion
There has been great interest in surveying genetic variants to pre-
dict potential response to clopidogrel. A number of commercial tests
have been developed that focus on two genes, CYP2C19 and ABCB1,esponder (n = 34) Non-responder (n = 71) p-Value
33 97.1% 48 67.6% 0.001
33 97.1% 67 94.4% 0.544
62.7 8.8 71.0 11.3 0.0001
86.6 20.7 84.6 15.5 0.577
76.3 8.8 170.6 10.0 0.006
2.05 0.28 2.00 0.22 0.323
27.77 5.81 29.03 4.47 0.224
22 64.7% 37 52.1% 0.224
13 38.2% 8 11.3% 0.001
9 26.5% 32 45.1% 0.052
33 97.1% 65 91.6% 0.290
0.98 0.2 1.14 0.6 0.138
1 2.9% 13 18.3% 0.024
0 0.0% 2 2.8% 0.323
32 94.1% 64 90.1% 0.496
0 0.0% 0 0.0% 1.000
3 8.8% 7 9.9% 0.785
1 2.9% 1 1.4% 0.591
3 8.8% 8 11.3% 0.702
1 2.9% 1 1.4% 0.591
21 61.8% 34 47.9% 0.183
1 2.9% 2 2.8% 0.971
3 8.8% 8 11.3% 0.702
14 41.2% 21 29.6% 0.238
2 5.9% 13 18.3% 0.089
28 82.4% 60 84.5% 0.779
3 8.8% 8 11.3% 0.702
30 88.2% 68 95.8% 0.039
19 55.9% 34 47.9% 0.433
29 85.3% 62 87.3% 0.229
3 8.8% 3 4.2% 0.342
16 47.1% 28 39.4% 0.532
0 0.0% 1 1.4% 0.487
26 76.5% 56 78.9% 0781
3 8.8% 18 25.4% 0.048
1 2.9% 1 1.4% 0.591
2.9 0.4 2.9 0.3 0.789
16 47.1% 40 56.3% 0.372
53.5 10.5 52.3 11.9 0.624
0 0.00% 1 1.41% 0.487
1 2.9% 7 11.3% 0.211
1 2.9% 8 12.5% 0.154
Table 2
Correlating genetic and VerifyNow results.
Table All Responder Non-responder
# of patients 105 34 32.38% 71 67.62%
Wild type 17 16.19% 7 20.59% 10 14.08%
Any mutation 88 83.81% 27 79.41% 61 85.92%
ABCB1 80 76.19% 25 73.53% 55 77.46%
+/+ 25 23.81% 9 26.47% 16 22.54%
+/− 54 51.43% 17 50.00% 37 52.11%
−/− 26 24.76% 8 23.53% 18 25.35%
CYP2C19 34 32.38% 10 29.41% 24 33.80%
CYP2C19*2
+/+ 74 70.48% 26 76.47% 48 67.61%
+/− 28 26.67% 7 20.59% 21 29.58%
−/− 3 2.86% 1 2.94% 2 2.82%
CYP2C19*4
+/+ 103 98.10% 33 97.06% 70 98.59%
+/− 2 1.90% 1 2.94% 1 1.41%
−/− 0 0.00% 0 0.00% 0 0.00%
CYP2C19*8
+/+ 104 99.05% 33 97.06% 71 100.00%
+/− 1 0.95% 1 2.94% 0 0.00%
−/− 0 0.00% 0 0.00% 0 0.00%
Both mutations 23 21.90% 8 23.53% 15 21.13%
Avg Plavix dose 233.6 219.5 308.8 244.8 197.5 198.1
Avg PRU 275.7 71.2 197.4 31.3 313.2 51.3
315M. Correll et al. / Genomics 101 (2013) 313–317which have been strongly linked to respond to the drug.We determined
the germline genetic sequence of these genes in 105 patients using
ultra-high throughput sequencing technologies that provide an unprec-
edented depth of coverage of the entire gene, allowing us to accurately
assess each of the purported informative variants. To our surprise, we
found little correlation between mutational status in these genes and
clopidogrel responsiveness, suggesting that there may be a number of
other genetic factors that contribute to determining the response. Our re-
sults clearly suggest genetic testing for clopidogrel resistance has low
sensitivity. Testing for mutations in CYP2C19, as recommended by the
FDA, only correctly predicted if a patient would respond to clopidogrel
52.4% of the time. Similarly, testing of the ABCB1 gene only correctly fore-
told response in 51 (48.6%) patients.
Our results are not consistent with those of the GIFT study [10]. This
may reﬂect the differences in design between the two studies. The GIFT
study researchers used a prospective, multinational, multicenter,
double-blind, randomized, and active-controlled approach, showing
that a strong relationship between CYP2C19 variants in PCI patients
and on-treatment reactivity (OTR) to clopidogrel exists. However, to
their own admission, the researchers stated that they selected for
patients with higher OTR levels [10]. Ours uses an observational ap-
proach that used a single, non-manipulated, surgical series of patients
from a single institution whom had been on clopidogrel prior to CABG,
reﬂecting a situation more in line with what practitioners face on a
daily basis.Table 3
Responder status of patients taking 75 mg clopidogrel daily.
All on 75 daily Responder Non-responder
Total 63 16 25.40% 47 74.60%
PRU 282.9 66.2 199.3 29.6 311.4 48.6
Wild type 8 q 2 12.50% 6 12.77%
Mutation 55 87.3% 14 87.50% 41 87.23%
CYP2C19 22 34.9% 6 37.50% 16 34.04%
CYP2C19*2 20 31.7% 4 25.00% 16 34.04%
+/− 18 28.6% 3 18.75% 15 31.91%
−/− 2 3.2% 1 6.25% 1 2.13%
CYP2C19*4 1 1.6% 1 6.25% 0 0.00%
CYP2C19*8 1 1.6% 1 6.25% 0 0.00%
ABCB1 47 74.60% 12 75.00% 35 74.47%
+/− 30 47.6% 7 43.75% 23 48.94%
−/− 17 27.0% 5 31.25% 12 25.53%
Both mutations 12 19.00% 4 25.00% 8 17.02%Current American College of Cardiologist (ACC)/American Heart
Association (AHA) guidelines recommend a 300–600 mg loading
dose of clopidogrel before PCI and a daily 75 mg dose for the follow-
ing 12 months [2]. In addition, clopidogrel should be discontinued
5 days before major surgery [2]. CYP2C19*2 heterozygotes require a
daily dose of 225 mg tomaintain “normal” platelet inhibition response,
which is triple the FDA recommended dose of 75 mg [17]. The *2/*2
homozygous patients do not reach normal range even with daily
doses of 300 mg [17] (Table 3).
In early 2009, the FDA ﬁrst warned the public about the effect of cer-
tain CYP2C19 variants on the effectiveness of clopidogrel, citing two
studies that found an association between CYP2C19 polymorphisms
and adverse clinical outcomes but did not expand further on the topic
[11,12,18]. Later that year, the FDA suggested physicians avoid prescrib-
ing clopidogrel to patients with known CYP2C19 polymorphisms [19].
The FDA revised the warning label in 2010 to indicate that physicians
“consider alternative treatment or treatment strategies in patients iden-
tiﬁed as CYP2C19 poor metabolizers” [16]. This label emphasizes the re-
sults of Gladding and colleagues' study of the pharmacokinetic and
antiplatelet response to clopidogrel. In this study, 40 patients were
put into four groups based upon responsiveness to clopidogrel (poor,
intermediate, extensive, and ultrarapid) based upon CYP2C19 variant
status [20]. Like our study, they used the results of a VerifyNow assay
to determine effectiveness of clopidogrel. They found that doubling
the dose (from 75 mg daily to 150 mg) of clopidogrel in patients with
CYP2C19*2 mutations reduced platelet reactivity by 26 ± 38 PRU.
While the FDA has recently reafﬁrmed its pro-genetic testing stance, it
is imperative to point out that the FDA does not mandate genetic
testing.
TheAmerican College of Chest Physicians, ACC, andAHA currently do
not support routine platelet function or genetic testing [21]. According
to the ACC/AHA's response to the 2010 label update, this is based on
the lack of strong “evidence-based data upon which to develop speciﬁc
recommendations on the role of genetic testing” [1]. They point out
that CYP2C19 polymorphisms are associated with just 12% of the vari-
ability in platelet response to clopidogrel [9]. Furthermore, studies
have shown CYP2C19 mutations to accurately predict adverse clinical
events in just 12–20% of patients receiving PCI [1]. The ACC/AHA also ex-
presses its concerns regarding the clinical impact of different polymor-
phisms and the effect of increased doses of clopidogrel [1]. In addition,
a recent meta-analysis of 32 studies on this topic showed no signiﬁcant
correlation between genotype and cardiovascular events [22].
The speciﬁcs of the VerifyNow test have been extensively deﬁned
[13,23]. In short, platelet reactivity can be quickly tested with low vol-
umes of whole blood. The test measures the degree of ADP-induced
inhibition of adenylyl cyclase, which is directly affected by clopid-
ogrel binding to the P2Y12 receptor [14]. The assay yields absolute
PRU values and calculates a percent P2Y12 inhibition [14,23]. The re-
sults of the VerifyNow assay are comparable to the light transmit-
tance aggregometry, Plateletworks, and Innovance PFA P2Y assays
[3–5,13,23]. VerifyNow received 501(k) clearance from the FDA to
be used clinically. The mean coefﬁcient of variation of test precision
is b8% in volunteers and 3.2% in patients with coronary artery disease
[13]. Multiple studies have used the VerifyNow assay as a method of
measuring platelet function and have found a PRU >240 to correlate
with increased risk for CV-related death, stent thrombus, and non-
fatal MI with a sensitivity of 78% and a speciﬁcity of 70% [14,23].
The assay is limited by the lack of a pre-clopidogrel baseline, creating
the space for potential inaccuracies when reporting the degree of plate-
let inhibition [13]. VerifyNow is less able to discriminate between strong
andweak P2Y12 inhibition signals than other PITs due to its smaller dy-
namic window [4]. Nonetheless, the VerifyNow assay is a trusted meth-
od of determining platelet inhibition levels.
In view of the data provided by the GIFT trial and our study as well
as others we can conclude the following: 1) in controlled situations,
particular gene variants inﬂuence clopidogrel reactivity, 2) while this
316 M. Correll et al. / Genomics 101 (2013) 313–317relationship may not be as strong in actuality, knowledge of this associ-
ation and how it can work in a non-manipulated setting can go far in
formulating and modifying recommendations on appropriate clopid-
ogrel use in clinical and surgical settings. We highly recommend that
these genetic ﬁndings be used in tandemwith other clinical tools to de-
termine the best course of treatment for these patients.
For subpopulations that are dependent on clopidogrel and com-
munities that have limited resources, it is imperative that pre- and
post-administration diagnostic tests be conducted to assure the med-
ical treatment is effective to reduce the chance for cardiovascular-
related readmissions and adverse events. While the use of clopidogrel
in clinical practice is not likely to end soon, the recent warnings by
the FDA underscore the danger of administering this drug without
full knowledge of its effects in non-responders. Employing clinically
useful and relevant screening tools will surely remedy the shortcom-
ings of any treatment.
3.1. Limitations
Our study used retrospective data but analyzed the information in
a prospective way. Furthermore, this study was conducted at a
medium-sized hospital. Results may have manifested differently in
larger or smaller institutions, but steps were taken to minimize bias
without compromising the goal or integrity of the study. Because
we sequenced only the exonic portions of the CYP2C19 and ABCB1
genes, we were not able to determine frequency of *17 variants
(T-808C) as the mutation occurs in an intron.
4. Materials and methods
4.1. Patient identiﬁcation
From June 2007 toNovember 2011, 1269 patients underwent isolat-
ed coronary artery bypass grafting (CABG) surgery. Of these, 105 pa-
tients were administered clopidogrel before surgery, were previously
included in the CV Blood and Tissue Bank at The Valley Hospital (IRB ap-
proval # 11.0009 and to the Helsinki declaration) and had the results of
a VerifyNow P2Y12 assay on ﬁle (Table 1). The patients gave consent to
gather blood samples for later use at the time of CABG. The mean age
was 68.3 years old with a body mass index of 28.6. The cohort favored
Caucasians (95.2%) and males (77.1%). This cohort of patients was not
artiﬁcially manipulated or selected based on predetermined character-
istics. Instead, it reﬂected a realistic sampling of the patient population
that an institution like ours would encounter.
4.2. Sample collection
At the time of surgery, patient's blood was drawn into a single
sterile 8 cm3 BD vacutainer cell preparation tube (CPT) with sodium
citrate and labeled accordingly. Immediately after blood draw, the
tube was carefully inverted 8–10 times to mix the anticoagulant
agent with the sample. Within 120 min, the tube was centrifuged at
room temperature for a minimum of 20 min at 1500–1800 RCF.
Using a thin pipette, the plasma layer (approximately 4 cm3) was
carefully removed and stored in a new sterile storage tube and frozen
at−70 °C. Using a second pipette, thewhite blood cell (WBC) layer (ap-
proximately 1.5 cm3) was transferred into a sterile 15 cm3 test tube.
The remaining sample containing the erythrocytes and granulocytes
was discarded as per hospital policy.
Phosphate-buffered saline solution was added to the WBCs to
bring the volume up to 15 mL and the solution was mixed by gentle
inversion. This mixture was then centrifuged for 15 min at 300 RCF
to allow complete separation of the WBC and the buffer; the superna-
tant was then discarded. Phosphate-buffered saline solution was then
added to the WBC pellet to bring the volume to 2 mL.The WBC solution was divided equally into two 1.5 mL sterile col-
lection tubes. The tubes were centrifuged for 10 min at 300 RCF and
then the supernatant was again decanted. The WBC pellets were la-
beled and stored in a −70 °C freezer. Pellets were put on dry ice,
placed in a secure container, and shipped to Dana-Farber Cancer Insti-
tute for genetic testing.
4.3. Genetic testing
DNA was extracted from the frozen the pellets using the Qiagen
DNeasy kit and prepared for targeted sequencing of ABCB1 and
CYP2C19. A panel of DNA primer pairs was designed to each of the
exons in the target genes for use with the Fluidigm AccessArray sys-
tem. Individual primers consist of a 30 bp universal segment and a
unique 20 bp segment. Each pair of primers is designed to hybridize
immediately upstream and downstream of a speciﬁc genomic target.
Supplementary Table 1 provides the genomic coordinates for the re-
gions targeted by our panel.
The sequence capture and library generation process involved by a
two-step PCRprocesswhere the ﬁrst PCR reaction captures an amplicon
from the region of interest, and a second reaction uses the universal
primer segment to append sample barcodes and Illumina sequencing
adapters. Bi-directional amplicon sequencing was performed on the
Illumina HiSeq 2000, and conﬁgured to generate 100 base-pair single-
end reads.
Sequencing reads were demultiplexed using the standard Illumina
pipeline. Reads from each sample were processed using a workﬂow de-
veloped speciﬁcally for this project. First, each read was mapped to one
of the 103 PCR primer pairs and trimmed to the initial portion of the
read based on the size (between 20 and 30 nucleotides in length) and
sequence of the primer. Second, reads that contain “empty” probes
(consisting of two primers ligated together without their target se-
quence) were identiﬁed and eliminated. Sequence-similarity searches
were performed usingmegablast from the NCBI BLAST package.
“Filtered” and trimmed reads were then aligned to the reference
Human genome (build hg19, GRCh37), using the open-source program
Bowtie [24] with the “-k” alignment mode with a seed size of 20 and up
to 5 allowablemismatches. After alignment, we called and ﬁltered SNPs
using the Samtools suite of programs [25]. We chose not to use the edge
and strand bias ﬁltering options as these were designed for random,
whole-genome sequencing and our targeted sequencing data has both
of these features by design. Supplementary Table 2 provides the speciﬁc
version number and parameter settings for the tools used in processing.
The mutational calls for all patients are provided in Supplementary
Table 3.
4.4. Platelet inhibition testing
Platelet inhibition was assessed using the VerifyNow P2Y12 assay.
The details of this test have been previously described elsewhere
[13,23]. In short, the assay uses a combination of prostaglandin E1 and
ADP to increase platelet cAMP, thereby increasing speciﬁcity and sensi-
tivity of the ADP-mediated effects of the P2Y12 receptor. The assay uses
light transmittance as a measure of ADP-induced platelet aggregation.
An algorithm interprets the data and reports the results in PRU. A high
PRU indicates greater platelet agglutination. The previously established
cut-off of 240 PRU was used to determine responder status.
4.5. Data analysis
Continuous data are displayed as means with standard deviation.
Categorical data are expressed as proportions. Categorical variables
and differences in rates between groups were analyzed using the chi-
squared test. A value of p b 0.05was used to determine the statistical
signiﬁcance of all tests used. Analyses were performed using the SPSS
statistical software package version 19.0 (IBM/SPSS Inc., Chicago, IL).
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